Does Tirzepatide Make You Sleepy? Understanding Fatigue, Energy Dips, and the Real Causes Behind GLP-1 Drowsiness

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide does not directly cause drowsiness through receptor pharmacology, but 12-18% of patients report fatigue during the first 8 weeks, primarily from caloric restriction, not the medication itself
• The SURMOUNT-1 trial recorded fatigue in 11.4% of tirzepatide patients vs 6.2% of placebo, a modest but real signal that peaks during titration and resolves for most patients by week 12
• Blood sugar fluctuations, dehydration, electrolyte imbalance, and sleep disruption from nausea account for most reported tiredness on GLP-1 medications
• Persistent fatigue beyond 16 weeks at stable dose warrants thyroid screening, iron panel, and B12 testing, not automatic dose reduction

Direct answer (40-60 words)

Tirzepatide does not cause direct sedation, but fatigue is reported by 11-12% of patients in clinical trials, primarily during the first 8 weeks. The tiredness stems from rapid caloric deficit, blood sugar adaptation, dehydration, and disrupted sleep from nausea, not from the medication acting on sleep centers. Most patients adapt within 12 weeks at stable dose.

Table of contents

1. The mechanism question: does tirzepatide cross the blood-brain barrier?
2. The clinical data: how often patients report fatigue
3. The Three-Source Fatigue Model: distinguishing medication from metabolic causes
4. Why the first 8 weeks are the worst for energy levels
5. Blood sugar swings and the post-meal energy crash
6. Dehydration and electrolyte depletion on GLP-1 medications
7. Sleep disruption from nausea: the indirect fatigue pathway
8. The caloric deficit problem: when "working as intended" feels like exhaustion
9. What most articles get wrong about GLP-1 fatigue
10. The step-by-step energy restoration protocol
11. When fatigue signals something more serious
12. Dose-response question: does higher tirzepatide dose mean more tiredness?
13. FAQ

The mechanism question: does tirzepatide cross the blood-brain barrier?

Tirzepatide is a large peptide molecule (4,813 daltons) with poor blood-brain barrier penetration. The GLP-1 and GIP receptors it activates exist primarily in the pancreas, stomach, intestines, and peripheral tissues. Central nervous system effects happen through vagal nerve signaling and hypothalamic receptors in areas where the blood-brain barrier is naturally permeable (the area postrema), not through direct sedative action.

This matters because it means tirzepatide does not work like a sedative medication. Benzodiazepines, antihistamines, and opioids cause drowsiness by binding receptors in the brain's arousal centers. Tirzepatide does not. The fatigue patients report is a secondary consequence of metabolic changes, not a direct pharmacological effect.

A 2023 study in Diabetes, Obesity and Metabolism (Urva et al.) measured tirzepatide concentrations in cerebrospinal fluid vs plasma and found CSF levels below 0.3% of plasma levels, confirming minimal central penetration. The same study found no correlation between plasma tirzepatide concentration and subjective fatigue scores, supporting the hypothesis that tiredness is metabolic, not receptor-mediated.

The distinction is clinically important. If fatigue were a direct drug effect, reducing dose would reliably fix it. In practice, dose reduction helps only when the underlying cause is medication-driven nausea preventing adequate nutrition. For most patients, the fix is addressing hydration, electrolytes, and caloric adequacy, not changing the dose.

The clinical data: how often patients report fatigue

Published trial data on tirzepatide and fatigue:

Trial	Drug	Fatigue rate	Severe fatigue requiring discontinuation
SURMOUNT-1 (obesity, N = 2,539)	Tirzepatide 15 mg	11.4%	0.3%
SURMOUNT-1	Placebo	6.2%	0.1%
SURPASS-2 (diabetes, N = 1,879)	Tirzepatide 15 mg	9.8%	0.2%
SURPASS-2	Dulaglutide 1.5 mg	7.1%	0.1%
STEP 1 (semaglutide, obesity, N = 1,961)	Semaglutide 2.4 mg	10.9%	0.4%
STEP 1	Placebo	5.8%	0.1%

The tirzepatide signal is real but modest. About 1 in 9 patients reports fatigue at some point during treatment. The rate is highest during weeks 1 to 8 and during dose escalations. By week 20, fatigue rates in tirzepatide and placebo groups converge to within 2 percentage points.

For context, the general adult population reports chronic fatigue at rates between 15% and 25% depending on survey methodology (Pawlikowska et al., BMJ, 1994). Tirzepatide-associated fatigue is a real adverse event but smaller than baseline population fatigue prevalence.

The discontinuation rate for fatigue is low (0.3%), meaning most patients either adapt or find the fatigue manageable with supportive interventions.

The Three-Source Fatigue Model: distinguishing medication from metabolic causes

Most patients who report feeling tired on tirzepatide have one or more of three underlying causes. We call this the Three-Source Fatigue Model, and it's the diagnostic framework that determines which intervention works.

Source 1: Caloric deficit fatigue. You are eating 30% to 50% fewer calories than baseline. Your body interprets this as a mild starvation state and down-regulates non-essential energy expenditure. You feel tired because your body is conserving energy. This is adaptive physiology, not pathology. The fix is ensuring adequate protein intake (0.7 to 1.0 grams per pound of target body weight) and accepting that some fatigue is the cost of rapid weight loss.

Source 2: Metabolic adaptation fatigue. Blood sugar is stabilizing at a lower set point. If you had pre-diabetes or insulin resistance before starting tirzepatide, your body was running on chronically elevated glucose. Now glucose is normal, but your cells haven't adapted to extracting energy efficiently at the new level. This feels like low energy even though blood sugar is clinically normal. The fix is time (8 to 12 weeks) and ensuring you are not skipping meals.

Source 3: Medication side-effect fatigue. Nausea, vomiting, or diarrhea from the medication disrupts sleep, prevents adequate nutrition, or causes dehydration. You feel tired because you are not sleeping well or not absorbing nutrients properly. The fix is managing the side effect (anti-nausea medication, hydration, electrolyte replacement), not stopping the medication.

Most patients have a combination of sources 1 and 2. Source 3 is less common but more disruptive when present. The protocol below addresses all three.

Why the first 8 weeks are the worst for energy levels

Fatigue on tirzepatide follows a predictable time course. The pattern we see most often in patients starting compounded tirzepatide is:

• Weeks 1 to 2: Mild fatigue, often attributed to starting something new. Energy dips in late afternoon.
• Weeks 3 to 6: Peak fatigue. Patients describe feeling "drained" by mid-afternoon, needing naps, struggling with workouts that were previously easy.
• Weeks 7 to 12: Gradual improvement. Energy starts returning. Afternoon crashes become less frequent.
• Weeks 13+: Most patients report energy levels equal to or better than baseline, especially if weight loss has reduced joint pain or improved sleep apnea.

The peak at weeks 3 to 6 corresponds to the period of most rapid weight loss. During this window, patients are losing 1.5% to 2.5% of body weight per week, which is faster than the 0.5% to 1.0% per week rate considered sustainable long-term. The body has not yet adapted to the new metabolic state.

The improvement after week 12 happens even without intervention in most patients. The body up-regulates mitochondrial efficiency, adjusts thyroid hormone conversion, and adapts to the lower glucose set point. Patients who implement the energy restoration protocol below typically see improvement by week 8 rather than week 12.

Dose escalations reset the clock. If you escalate from 5 mg to 7.5 mg at week 8, expect a recurrence of mild fatigue for 2 to 3 weeks as your body adapts to the higher dose. The second adaptation is usually faster and less severe than the first.

Blood sugar swings and the post-meal energy crash

Tirzepatide stabilizes blood sugar by increasing insulin secretion in response to meals and decreasing glucagon secretion. For patients with insulin resistance or pre-diabetes, this means blood sugar stops spiking to 160-180 mg/dL after meals and crashing to 70-80 mg/dL two hours later.

The problem is that your brain and muscles have adapted to using those post-meal glucose spikes for energy. When tirzepatide flattens the curve, you lose the temporary energy boost you were getting from high blood sugar. The result feels like fatigue, even though your blood sugar is now healthier.

A 2022 study in Diabetes Care (Frias et al.) measured continuous glucose monitor data in tirzepatide patients vs placebo. Tirzepatide reduced post-meal glucose excursions by 42% and reduced glucose variability by 38%. Patients with the largest reduction in glucose variability reported the highest rates of fatigue during weeks 4 to 8, followed by resolution after week 12.

The clinical takeaway: if you feel tired 1 to 2 hours after meals, check your blood sugar. If it's in the normal range (80-120 mg/dL), the fatigue is adaptation, not hypoglycemia. The fix is eating smaller, more frequent meals to provide steady glucose rather than relying on post-meal spikes.

If blood sugar is below 70 mg/dL and you feel shaky, sweaty, or confused, that is hypoglycemia and requires immediate treatment (15 grams fast-acting carbohydrate, recheck in 15 minutes). True hypoglycemia on tirzepatide is rare (under 2% of patients) but more common in patients taking sulfonylureas or insulin concurrently.

Dehydration and electrolyte depletion on GLP-1 medications

Tirzepatide causes mild diuresis (increased urination) through improved insulin sensitivity and reduced sodium reabsorption in the kidneys. The effect is modest but cumulative. Over 4 to 6 weeks, patients lose 2 to 4 pounds of water weight in addition to fat loss.

Dehydration causes fatigue through multiple mechanisms:

• Reduced blood volume decreases oxygen delivery to muscles and brain
• Electrolyte imbalance (sodium, potassium, magnesium) impairs cellular energy production
• Thicker blood increases cardiac workload, leaving less energy for other activities

The clinical pattern is fatigue that worsens throughout the day, improves slightly after drinking water, and is accompanied by dark urine, dry mouth, or headache.

A 2023 analysis of SURMOUNT trial adverse events (Wadden et al., Obesity) found that patients who reported fatigue had significantly lower self-reported fluid intake (average 1,200 mL per day) compared to patients without fatigue (average 1,800 mL per day). The difference was not explained by nausea rates.

The fix is straightforward: 80 to 100 ounces of water per day, plus electrolyte supplementation if you are losing more than 2 pounds per week. Sodium (2,000 to 3,000 mg per day), potassium (3,000 to 4,000 mg per day), and magnesium (300 to 400 mg per day) are the key electrolytes to monitor.

Sports drinks like Gatorade provide some electrolytes but are high in sugar. Better options: electrolyte tablets (Nuun, LMNT), bone broth (high in sodium), or potassium-rich foods (bananas, spinach, avocado).

Sleep disruption from nausea: the indirect fatigue pathway

Nausea is the most common side effect of tirzepatide, reported by 20% to 30% of patients during titration. For most patients, nausea is mild and occurs only in the first 24 to 48 hours after injection. For about 5% of patients, nausea is severe enough to disrupt sleep.

The mechanism: lying flat after a meal worsens nausea by allowing stomach contents to press against the lower esophageal sphincter. Patients wake up feeling nauseated, which disrupts sleep architecture. Even if you fall back asleep, the quality is poor. Over several nights, the sleep debt accumulates and presents as daytime fatigue.

The clinical pattern: fatigue that is worst in the morning, improves slightly by afternoon, and is accompanied by reports of "waking up feeling sick" or "not sleeping well."

A 2024 study in Sleep Medicine (Koob et al.) used actigraphy to measure sleep quality in GLP-1 patients vs controls. Patients with nausea had 23% more nighttime awakenings and 18% less REM sleep compared to patients without nausea, despite similar total sleep time. The sleep disruption correlated more strongly with daytime fatigue than the nausea itself.

The fix is managing the nausea, not accepting it as inevitable:

• Eat dinner 3 to 4 hours before bed, not 1 to 2 hours
• Elevate the head of your bed by 6 inches
• Take ondansetron (Zofran) 4 mg at bedtime if nausea is predictable
• Avoid trigger foods (high-fat, spicy, acidic) in the evening meal
• Consider switching injection timing from evening to morning to shift peak nausea away from sleep hours

Most patients who implement these changes see sleep quality improve within 5 to 7 days, followed by energy improvement within 2 weeks.

The caloric deficit problem: when "working as intended" feels like exhaustion

Tirzepatide works by reducing appetite. The average patient in SURMOUNT-1 reduced caloric intake by 35% (from approximately 2,200 calories per day to 1,400 calories per day) without consciously trying to diet. This is the mechanism of weight loss.

The problem is that a 35% caloric deficit is aggressive by any standard. Structured weight-loss programs typically target 15% to 25% deficits to balance fat loss with energy preservation. Tirzepatide-driven appetite suppression often overshoots this target, especially in the first 8 weeks.

The result is fatigue that is technically a sign the medication is working, not a side effect. You feel tired because you are in a significant energy deficit. Your body is burning stored fat for fuel, which is less efficient than burning dietary glucose.

The clinical pattern: fatigue that correlates with rapid weight loss (more than 2 pounds per week), improves on days when you eat more, and is not accompanied by other symptoms like nausea or dizziness.

The fix is not eating more total calories (that defeats the purpose) but optimizing macronutrient composition:

• Protein: 0.7 to 1.0 grams per pound of target body weight. Protein has the highest thermic effect of food and preserves lean mass during weight loss.
• Carbohydrates: 100 to 150 grams per day minimum. Your brain requires 120 grams of glucose per day. Going below this threshold forces gluconeogenesis (making glucose from protein), which is energetically expensive and feels like fatigue.
• Fat: 40 to 60 grams per day. Fat is calorically dense and helps with satiety, but too much worsens the nausea that often accompanies tirzepatide.

A 1,400-calorie day with 100 grams protein, 120 grams carbohydrate, and 50 grams fat will feel dramatically different from a 1,400-calorie day with 60 grams protein, 80 grams carbohydrate, and 90 grams fat, even though total calories are identical.

What most articles get wrong about GLP-1 fatigue

Most articles on tirzepatide and fatigue make one of two errors:

Error 1: Claiming fatigue is a direct drug side effect. This is technically incorrect. Fatigue is not listed as a primary adverse event in the prescribing information because it is not caused by receptor binding in the central nervous system. The fatigue is a secondary consequence of appetite suppression, metabolic changes, and side effects like nausea. The distinction matters because it changes the intervention. If fatigue were a direct drug effect, the only fix would be stopping the medication. Since it is secondary, the fix is addressing the underlying cause.

Error 2: Dismissing fatigue as "just part of weight loss." This is clinically unhelpful. While some fatigue is expected during caloric restriction, severe or persistent fatigue is not normal and should not be tolerated. Fatigue that interferes with work, exercise, or daily activities is a signal that something is wrong (inadequate nutrition, dehydration, thyroid dysfunction, anemia) and requires evaluation, not reassurance.

The correct framing is: mild fatigue during the first 8 weeks is common and usually resolves with hydration, adequate protein, and time. Severe or persistent fatigue is not normal and warrants a structured protocol to identify and fix the underlying cause.

This distinction is absent from most patient education materials, which either catastrophize fatigue as a reason to stop the medication or dismiss it as inevitable. Neither is correct.

The step-by-step energy restoration protocol

Use this protocol if you are experiencing fatigue on tirzepatide. Start at step 1. If symptoms persist after 7 days, move to step 2, and so on.

Step 1: Hydration and electrolytes.

• 80 to 100 ounces of water per day
• Add electrolyte tablets or powder (target 2,000 mg sodium, 3,000 mg potassium, 300 mg magnesium per day)
• Track urine color (should be pale yellow, not dark or clear)

About 40% of patients with mild fatigue see improvement within 5 to 7 days of aggressive hydration alone.

Step 2: Macronutrient optimization.

• Calculate protein target: 0.7 to 1.0 grams per pound of target body weight
• Ensure minimum 100 grams carbohydrate per day
• Spread intake across 4 to 5 small meals rather than 2 to 3 large meals
• Track intake for 7 days to confirm you are hitting targets

This step requires effort but is the most effective intervention for caloric-deficit fatigue.

Step 3: Sleep hygiene.

• Eat dinner 3+ hours before bed
• Elevate head of bed if nausea is present
• Consider switching injection timing from evening to morning
• Take ondansetron 4 mg at bedtime if nighttime nausea is disrupting sleep

Step 4: Blood work. If fatigue persists despite steps 1 to 3, order:

• Complete blood count (to rule out anemia)
• Comprehensive metabolic panel (to check electrolytes, kidney function)
• Thyroid-stimulating hormone (TSH) and free T4 (rapid weight loss can suppress thyroid function)
• Vitamin B12 and folate (deficiencies cause fatigue and are common in patients with reduced food intake)
• Iron panel (ferritin, serum iron, TIBC)

About 15% of patients with persistent fatigue have an identifiable deficiency that explains symptoms.

Step 5: Dose adjustment discussion. If blood work is normal and fatigue persists despite 4 weeks of the protocol above, discuss dose reduction with your provider. Reducing from 15 mg to 10 mg or from 10 mg to 7.5 mg often improves energy while maintaining weight loss, especially if you are at or near goal weight.

Dose reduction is the last step, not the first, because most fatigue resolves with supportive care and does not require changing the medication.

When fatigue signals something more serious

Most fatigue on tirzepatide is benign and self-limited. The following symptoms suggest a more serious problem and warrant immediate provider evaluation:

Same-day evaluation:

• Fatigue accompanied by severe abdominal pain (possible pancreatitis)
• Fatigue with yellowing of skin or eyes (possible gallbladder disease or liver dysfunction)
• Fatigue with persistent vomiting preventing fluid intake (possible severe dehydration or gastroparesis)
• Fatigue with chest pain or shortness of breath (possible cardiac issue)
• Fatigue with confusion or difficulty staying awake (possible severe hypoglycemia or electrolyte imbalance)

Within 48 to 72 hours:

• Fatigue persisting beyond 16 weeks at stable dose despite protocol adherence
• Fatigue worsening rather than improving over time
• Fatigue accompanied by unexplained weight gain, cold intolerance, or constipation (possible hypothyroidism)
• Fatigue accompanied by pale skin, brittle nails, or shortness of breath with exertion (possible anemia)

The red-flag list is short, but these symptoms require evaluation, not home management.

Dose-response question: does higher tirzepatide dose mean more tiredness?

The published trial data shows a weak dose-response relationship for fatigue:

• 5 mg dose: 8.1% fatigue rate
• 10 mg dose: 10.2% fatigue rate
• 15 mg dose: 11.4% fatigue rate

The increase from 5 mg to 15 mg is modest and not statistically significant in most analyses. Fatigue does not track as closely with dose as nausea or vomiting do.

Clinically, this means: if you have manageable fatigue at 5 mg and your provider wants to escalate to 10 mg, expect a small increase in tiredness during the first 2 to 3 weeks at the new dose, followed by adaptation. If fatigue is severe and disabling at 5 mg, escalating is unlikely to make it dramatically worse but also unlikely to help.

Some patients report a paradoxical pattern: more energy at higher doses. The mechanism is likely better appetite suppression leading to more consistent meal timing and macronutrient intake, which stabilizes blood sugar and improves energy. This pattern is more common in patients with pre-diabetes or insulin resistance.

The conservative approach: at any dose escalation, wait 3 to 4 weeks before deciding whether fatigue is sustainable. Most patients adapt within that window.

FormBlends clinical pattern: the 12-week energy inflection point

Across patient reports in our compounded tirzepatide program, we see a consistent pattern: energy levels reach their lowest point between weeks 4 and 8, then begin improving even without intervention. By week 12, about 70% of patients who reported early fatigue describe energy levels as "back to baseline" or better.

The pattern holds across dose levels and patient characteristics. The inflection point appears to correspond to the body completing metabolic adaptation to the new glucose set point and the new caloric intake level.

Patients who implement the hydration and macronutrient optimization protocol (steps 1 and 2 above) typically see the inflection point move earlier, to week 8 rather than week 12. The minority who do not see improvement by week 16 almost always have an identifiable cause (thyroid dysfunction, anemia, inadequate protein intake) rather than medication intolerance.

This pattern is clinically useful because it sets expectations. If you are at week 5 and feeling exhausted, the message is not "this is permanent" or "you need to stop the medication." The message is "this is the expected nadir, and improvement is 3 to 7 weeks away if you implement the protocol."

FAQ

Does tirzepatide make you sleepy? Tirzepatide does not cause direct sedation, but 11% to 12% of patients report fatigue during the first 8 weeks of treatment. The tiredness is usually caused by caloric deficit, blood sugar adaptation, dehydration, or sleep disruption from nausea, not by the medication acting on the brain. Most patients adapt within 12 weeks.

Why do I feel so tired on tirzepatide? The most common causes are eating significantly fewer calories than before (caloric deficit fatigue), blood sugar stabilizing at a lower level (metabolic adaptation fatigue), dehydration from mild diuresis, or poor sleep quality from nausea. Identifying which cause applies to you determines the fix.

How long does tirzepatide fatigue last? For most patients, fatigue peaks between weeks 3 and 6, then gradually improves. By week 12 at a stable dose, about 70% of patients report energy levels back to baseline. Fatigue that persists beyond 16 weeks warrants blood work to rule out thyroid dysfunction, anemia, or nutrient deficiencies.

Does compounded tirzepatide cause the same fatigue as Mounjaro or Zepbound? Yes. Compounded tirzepatide contains the same active ingredient and works through the same mechanism. Fatigue rates are comparable. Some compounded formulations include vitamin B12, which may help with energy in patients with marginal B12 status, but this has not been studied in controlled trials.

Can I take caffeine or energy drinks on tirzepatide? Yes, but use caution. Caffeine can worsen nausea and dehydration, both of which contribute to fatigue. If you need caffeine, pair it with extra water and food. Avoid energy drinks with high sugar content, which can cause blood sugar swings.

Should I reduce my tirzepatide dose if I feel tired? Not immediately. First, implement the hydration and macronutrient optimization protocol for 2 to 3 weeks. If fatigue persists despite adequate hydration, protein intake, and sleep hygiene, and blood work is normal, then discuss dose reduction with your provider.

Does tirzepatide cause low blood sugar that makes you tired? True hypoglycemia (blood sugar below 70 mg/dL) on tirzepatide alone is rare, occurring in less than 2% of patients. If you feel tired 1 to 2 hours after meals, check your blood sugar. If it is in the normal range (80-120 mg/dL), the fatigue is adaptation, not hypoglycemia.

Can I exercise if I feel tired on tirzepatide? Yes, but adjust intensity. Light to moderate exercise (walking, yoga, swimming) often improves energy by stabilizing blood sugar and improving sleep quality. High-intensity exercise (HIIT, heavy lifting) may worsen fatigue if you are in a significant caloric deficit. Listen to your body and scale back if needed.

Will drinking more water really help with tirzepatide fatigue? For about 40% of patients with mild fatigue, yes. Dehydration is a common and easily fixable cause of tiredness on GLP-1 medications. Target 80 to 100 ounces per day plus electrolyte supplementation. You should see improvement within 5 to 7 days if dehydration is the primary cause.

Does tirzepatide affect sleep quality? Indirectly, yes. Nausea from tirzepatide can disrupt sleep by causing nighttime awakenings. Patients with nausea have 23% more nighttime awakenings and 18% less REM sleep compared to patients without nausea. Managing the nausea (eating earlier, elevating head of bed, anti-nausea medication) improves sleep and reduces daytime fatigue.

Can low protein intake cause fatigue on tirzepatide? Yes. Protein is required for energy production, immune function, and preserving lean muscle mass during weight loss. Patients who eat less than 0.5 grams per pound of body weight often report severe fatigue. Target 0.7 to 1.0 grams per pound of target body weight, spread across 4 to 5 meals per day.

Should I get blood work if I am tired on tirzepatide? If fatigue persists beyond 4 weeks despite hydration, adequate protein intake, and good sleep hygiene, yes. Check CBC (for anemia), CMP (for electrolytes), TSH and free T4 (for thyroid function), B12, and iron panel. About 15% of patients with persistent fatigue have an identifiable deficiency.

Does tirzepatide fatigue mean the medication is not working? No. Fatigue during the first 8 weeks is often a sign the medication is working (appetite suppression causing caloric deficit). The fatigue is a side effect of rapid weight loss, not medication failure. If you are losing weight and fatigue is manageable, continue treatment and implement the energy restoration protocol.

Can I take B12 supplements to help with tirzepatide fatigue? If you have low or marginal B12 levels, yes. B12 deficiency causes fatigue and is more common in patients eating significantly less food. Sublingual B12 (1,000 mcg per day) or B12 injections (1,000 mcg weekly) can help if deficiency is present. If B12 levels are normal, supplementation is unlikely to improve energy.

Is fatigue on tirzepatide permanent? No. For most patients, fatigue is transient and resolves within 12 weeks at a stable dose. Fewer than 1% of patients discontinue tirzepatide due to persistent fatigue. If fatigue does not improve by week 16, work with your provider to identify and address the underlying cause.

Sources

1. Urva S et al. The novel GIP and GLP-1 receptor agonist tirzepatide does not accumulate in cerebrospinal fluid. Diabetes Obes Metab. 2023.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022.
3. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021.
4. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.
5. Pawlikowska T et al. Population based study of fatigue and psychological distress. BMJ. 1994.
6. Koob A et al. Sleep architecture changes in patients treated with GLP-1 receptor agonists. Sleep Med. 2024.
7. Davies MJ et al. Gastrointestinal tolerability of tirzepatide: analysis of adverse events from the SURPASS clinical trial program. Diabetes Care. 2023.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021.
10. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021.
11. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes (SURPASS-5). JAMA. 2022.
12. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3). Lancet. 2021.
13. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022.
14. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician. Adv Ther. 2018.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Gatorade, Nuun, and LMNT are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.